Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 498

1.

Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State.

Grivas P, Monk BJ, Petrylak D, Reck M, Foley G, Guenther S, Hennessy D, Makris C, Moehler M.

Target Oncol. 2019 Sep 18. doi: 10.1007/s11523-019-00665-1. [Epub ahead of print] Review.

PMID:
31535338
2.

Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.

Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Colombo N, Mirza MR, Monk BJ, Tsibulak I, Calvert PM, Herzog TJ, Hanker LC, Meunier J, Lee JY, Bologna A, Carrasco-Alfonso MJ, Harter P.

Gynecol Oncol. 2019 Sep 10. pii: S0090-8258(19)31476-3. doi: 10.1016/j.ygyno.2019.08.024. [Epub ahead of print]

3.

Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma.

Tewari KS, Monk BJ.

J Clin Oncol. 2019 Sep 20;37(27):2472-2489. doi: 10.1200/JCO.18.02303. Epub 2019 Aug 12. No abstract available.

PMID:
31403858
4.

The American Society of Clinical Oncology 2019 annual meeting: A review and summary of selected abstracts.

Duska LR, Gibson SJ, Beall SC, Monk BJ.

Gynecol Oncol. 2019 Sep;154(3):454-460. doi: 10.1016/j.ygyno.2019.06.019. Epub 2019 Jul 12. No abstract available.

PMID:
31303254
5.

Attenuated apoptotic BAX expression as a xenobiotic reporter in Saccharomyces cerevisiae.

Keniya MV, Monk BC.

FEMS Yeast Res. 2019 Aug 1;19(5). pii: foz048. doi: 10.1093/femsyr/foz048.

PMID:
31291458
6.

Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.

Fuh KC, Java JJ, Chan JK, Kapp DS, Monk BJ, Burger RA, Young RC, Alberts DS, McGuire WP, Markman M, Bell J, Ozols RF, Armstrong DK, Aghajanian C, Bookman MA, Mannel RS.

Gynecol Oncol. 2019 Aug;154(2):420-425. doi: 10.1016/j.ygyno.2019.05.013. Epub 2019 Jun 19.

PMID:
31229298
7.

Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.

Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, Fowler JM, Greer BE, Boente M, Liang SX, Ye C, Bais C, Randall LM, Chan JK, Ferriss JS, Coleman RL, Aghajanian C, Herzog TJ, DiSaia PJ, Copeland LJ, Mannel RS, Birrer MJ, Monk BJ.

J Clin Oncol. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19.

PMID:
31216226
8.

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.

Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR.

J Clin Oncol. 2019 Jun 7:JCO1802238. doi: 10.1200/JCO.18.02238. [Epub ahead of print]

PMID:
31173551
9.

Stress transforms lateral habenula reward responses into punishment signals.

Shabel SJ, Wang C, Monk B, Aronson S, Malinow R.

Proc Natl Acad Sci U S A. 2019 Jun 18;116(25):12488-12493. doi: 10.1073/pnas.1903334116. Epub 2019 May 31.

PMID:
31152135
10.

The Evolving Landscape of Chemotherapy in Newly Diagnosed Advanced Epithelial Ovarian Cancer.

Monk BJ, Randall LM, Grisham RN.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:e141-e151. doi: 10.1200/EDBK_239007. Epub 2019 May 17.

PMID:
31099631
11.

Features of the cervicovaginal microenvironment drive cancer biomarker signatures in patients across cervical carcinogenesis.

Łaniewski P, Cui H, Roe DJ, Barnes D, Goulder A, Monk BJ, Greenspan DL, Chase DM, Herbst-Kralovetz MM.

Sci Rep. 2019 May 14;9(1):7333. doi: 10.1038/s41598-019-43849-5.

12.

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators.

Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.

PMID:
31076365
13.

A GCIG international survey: clinical practice patterns of sentinel lymph node biopsies in cervical cancer.

Vercellino GF, Erdemoglu E, Lichtenberg P, Muallem MZ, Richter R, Abu-Rustum NR, Plante M, Lécuru F, Greggi S, Monk BJ, Sagae S, Denkert C, Keller M, Alhakeem M, Hellriegel M, Dückelmann AM, Chiantera V, Sehouli J.

Arch Gynecol Obstet. 2019 Jul;300(1):191-199. doi: 10.1007/s00404-019-05164-2. Epub 2019 Apr 21.

PMID:
31006839
14.

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.

Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ.

Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Erratum in: Lancet Oncol. 2019 May;20(5):e242.

PMID:
30948273
15.

Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.

Buechel M, Herzog TJ, Westin SN, Coleman RL, Monk BJ, Moore KN.

Ann Oncol. 2019 May 1;30(5):721-732. doi: 10.1093/annonc/mdz104.

PMID:
30887020
16.

Fungal Lanosterol 14α-demethylase: A target for next-generation antifungal design.

Monk BC, Sagatova AA, Hosseini P, Ruma YN, Wilson RK, Keniya MV.

Biochim Biophys Acta Proteins Proteom. 2019 Mar 6. pii: S1570-9639(19)30044-5. doi: 10.1016/j.bbapap.2019.02.008. [Epub ahead of print] Review.

PMID:
30851431
17.

Relationship between social support, quality of life, and Th2 cytokines in a biobehavioral cancer survivorship trial.

Osann K, Wilford J, Wenzel L, Hsieh S, Tucker JA, Wahi A, Monk BJ, Nelson EL.

Support Care Cancer. 2019 Sep;27(9):3301-3310. doi: 10.1007/s00520-018-4617-z. Epub 2019 Jan 5.

PMID:
30612237
18.

Response to "surgical management of cervical cancer by laparoscopy or laparotomy".

Leath CA 3rd, Monk BJ.

Gynecol Oncol Rep. 2018 Nov 20;27:6-7. doi: 10.1016/j.gore.2018.11.005. eCollection 2019 Feb. No abstract available.

19.

Azole Resistance Reduces Susceptibility to the Tetrazole Antifungal VT-1161.

Monk BC, Keniya MV, Sabherwal M, Wilson RK, Graham DO, Hassan HF, Chen D, Tyndall JDA.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e02114-18. doi: 10.1128/AAC.02114-18. Print 2019 Jan.

20.

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.

Monk BJ, Kauderer JT, Moxley KM, Bonebrake AJ, Dewdney SB, Secord AA, Ueland FR, Johnston CM, Aghajanian C.

Gynecol Oncol. 2018 Dec;151(3):422-427. doi: 10.1016/j.ygyno.2018.10.001. Epub 2018 Oct 8.

PMID:
30309721
21.

The American Society of Clinical Oncology 2018 annual meeting: A review and summary of selected abstracts.

Rimel BJ, Gibson SJ, Beall SC, Monk BJ.

Gynecol Oncol. 2018 Nov;151(2):e1-e6. doi: 10.1016/j.ygyno.2018.08.018. Epub 2018 Aug 31. No abstract available.

PMID:
30174175
22.

Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm.

Arend RC, Toboni MD, Montgomery AM, Burger RA, Olawaiye AB, Monk BJ, Herzog TJ.

Oncologist. 2018 Dec;23(12):1533-1545. doi: 10.1634/theoncologist.2018-0095. Epub 2018 Aug 23.

PMID:
30139839
23.

Crystal Structures of Full-Length Lanosterol 14α-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provide Tools for Antifungal Discovery.

Keniya MV, Sabherwal M, Wilson RK, Woods MA, Sagatova AA, Tyndall JDA, Monk BC.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01134-18. doi: 10.1128/AAC.01134-18. Print 2018 Nov.

24.

Heterologous Expression of Full-Length Lanosterol 14α-Demethylases of Prominent Fungal Pathogens Candida albicans and Candida glabrata Provides Tools for Antifungal Discovery.

Keniya MV, Ruma YN, Tyndall JDA, Monk BC.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01131-18. doi: 10.1128/AAC.01131-18. Print 2018 Nov.

25.

Validation of PROMIS emotional distress short form scales for cervical cancer.

Wilford J, Osann K, Hsieh S, Monk B, Nelson E, Wenzel L.

Gynecol Oncol. 2018 Oct;151(1):111-116. doi: 10.1016/j.ygyno.2018.07.022. Epub 2018 Aug 2.

PMID:
30078504
26.

Comment on Pyrexia of unknown origin.

Monk B.

Clin Med (Lond). 2018 Aug;18(4):351. doi: 10.7861/clinmedicine.18-4-351a. No abstract available.

27.

The utility of patient reported data in a gynecologic oncology clinic.

Barnes D, Rivera R, Gibson S, Craig C, Cragun J, Monk B, Chase D.

Gynecol Oncol Res Pract. 2018 Jul 12;5:4. doi: 10.1186/s40661-018-0062-4. eCollection 2018.

28.

Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years.

Leath CA 3rd, Monk BJ.

Gynecol Oncol. 2018 Sep;150(3):391-397. doi: 10.1016/j.ygyno.2018.06.023. Epub 2018 Jun 27. Review.

29.

A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).

Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM.

Gynecol Oncol. 2018 Aug;150(2):247-252. doi: 10.1016/j.ygyno.2018.05.029. Epub 2018 Jun 18.

30.

A neural pathway controlling motivation to exert effort.

Proulx CD, Aronson S, Milivojevic D, Molina C, Loi A, Monk B, Shabel SJ, Malinow R.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):5792-5797. doi: 10.1073/pnas.1801837115. Epub 2018 May 11.

31.

The hazards of neglecting the skin.

Monk B.

Clin Med (Lond). 2018 Mar;18(2):189-190. doi: 10.7861/clinmedicine.18-2-189b. No abstract available.

32.

Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.

Pujade-Lauraine E, Fujiwara K, Dychter SS, Devgan G, Monk BJ.

Future Oncol. 2018 Sep;14(21):2103-2113. doi: 10.2217/fon-2018-0070. Epub 2018 Mar 27.

33.

Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.

Friedlander M, Rau J, Lee CK, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, Hilpert F, King MT, Debruyne P, Bologna A, Malander S, Monk BJ, Petru E, Calvert P, Herzog TJ, Barrett C, du Bois A.

Ann Oncol. 2018 Mar 1;29(3):737-743. doi: 10.1093/annonc/mdx796.

PMID:
29267856
34.

Impact of Homologous Resistance Mutations from Pathogenic Yeast on Saccharomyces cerevisiae Lanosterol 14α-Demethylase.

Sagatova AA, Keniya MV, Tyndall JDA, Monk BC.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e02242-17. doi: 10.1128/AAC.02242-17. Print 2018 Mar.

35.

Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?

Monk BJ, Chan JK.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii40-viii45. doi: 10.1093/annonc/mdx451. Review.

PMID:
29232474
36.

Impact of tumour histology on survival in advanced cervical carcinoma: an NRG Oncology/Gynaecologic Oncology Group Study.

Seamon LG, Java JJ, Monk BJ, Penson RT, Brown J, Mannel RS, Oaknin A, Leitao MM, Eisenhauer EL, Long HJ, Liao SY, Tewari KS.

Br J Cancer. 2018 Jan;118(2):162-170. doi: 10.1038/bjc.2017.400. Epub 2017 Nov 28.

37.

Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14α-demethylase.

Caramalho R, Tyndall JDA, Monk BC, Larentis T, Lass-Flörl C, Lackner M.

Sci Rep. 2017 Nov 21;7(1):15898. doi: 10.1038/s41598-017-16123-9.

38.

Optimal treatment for platinum-sensitive recurrent ovarian cancer.

Monk BJ.

Clin Adv Hematol Oncol. 2017 Sep;15(9):674-676. No abstract available.

PMID:
28949936
39.

Bringing new medicines to women with epithelial ovarian cancer: what is the unmet medical need?

Herzog TJ, Monk BJ.

Gynecol Oncol Res Pract. 2017 Sep 7;4:13. doi: 10.1186/s40661-017-0050-0. eCollection 2017. Review.

40.

FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.

Herzog TJ, Ison G, Alvarez RD, Balasubramaniam S, Armstrong DK, Beaver JA, Ellis A, Tang S, Ford P, McKee A, Gershenson DM, Kim G, Monk BJ, Pazdur R, Coleman RL.

Gynecol Oncol. 2017 Oct;147(1):3-10. doi: 10.1016/j.ygyno.2017.08.012. Epub 2017 Aug 24. Review. No abstract available.

PMID:
28844539
41.

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, DiSaia PJ, Copeland LJ, Creasman WT, Stehman FB, Brady MF, Burger RA, Thigpen JT, Birrer MJ, Waggoner SE, Moore DH, Look KY, Koh WJ, Monk BJ.

Lancet. 2017 Oct 7;390(10103):1654-1663. doi: 10.1016/S0140-6736(17)31607-0. Epub 2017 Jul 27.

42.

Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study.

Phippen NT, Secord AA, Wolf S, Samsa G, Davidson B, Abernethy AP, Cella D, Havrilesky LJ, Burger RA, Monk BJ, Leath CA 3rd.

Gynecol Oncol. 2017 Oct;147(1):98-103. doi: 10.1016/j.ygyno.2017.07.121. Epub 2017 Jul 23.

43.

A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.

Chan JK, Deng W, Higgins RV, Tewari KS, Bonebrake AJ, Hicks M, Gaillard S, Ramirez PT, Chafe W, Monk BJ, Aghajanian C.

Gynecol Oncol. 2017 Sep;146(3):554-559. doi: 10.1016/j.ygyno.2017.05.033. Epub 2017 Jul 18.

44.

Therapeutic options for treatment of human papillomavirus-associated cancers - novel immunologic vaccines: ADXS11-001.

Miles B, Safran HP, Monk BJ.

Gynecol Oncol Res Pract. 2017 Jul 14;4:10. doi: 10.1186/s40661-017-0047-8. eCollection 2017. Review.

45.

The American Society of Clinical Oncology 2017 Annual Meeting: A review and summary of selected abstracts.

Rimel BJ, Gibson SJ, Sumner DA, Monk BJ.

Gynecol Oncol. 2017 Sep;146(3):443-448. doi: 10.1016/j.ygyno.2017.06.030. Epub 2017 Jul 8. No abstract available.

PMID:
28693948
46.

Efficacy and safety of trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial.

Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, Rushing D, Milhem M, Monk B, Wang G, McCarthy S, Knoblauch RE, Parekh TV, Maki RG, Demetri GD.

Gynecol Oncol. 2017 Sep;146(3):531-537. doi: 10.1016/j.ygyno.2017.06.018. Epub 2017 Jun 24.

47.

Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy.

Miles BA, Monk BJ, Safran HP.

Gynecol Oncol Res Pract. 2017 Jun 2;4:9. doi: 10.1186/s40661-017-0046-9. eCollection 2017. Review.

48.

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study.

Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G.

Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049.

49.

Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.

Graybill WS, Pothuri B, Chase DM, Monk BJ.

Gynecol Oncol. 2017 Jul;146(1):11-15. doi: 10.1016/j.ygyno.2017.03.508. Epub 2017 Apr 6. No abstract available.

PMID:
28392129
50.

Will bevacizumab biosimilars impact the value of systemic therapy in gynecologic cancers?

Monk BJ, Huh WK, Rosenberg JA, Jacobs I.

Gynecol Oncol Res Pract. 2017 Mar 21;4:7. doi: 10.1186/s40661-017-0045-x. eCollection 2017. Review.

Supplemental Content

Support Center